TrialBritish journal of cancer2010

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

T Trarbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.